Jinsoo Hong1, Shuiyu Lu1, Rong Xu1, Jeih-San Liow1, Alicia E Woock1, Kimberly J Jenko1, Robert L Gladding1, Sami S Zoghbi1, Robert B Innis1, Victor W Pike2. 1. Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Room B3 C346A, 10 Center Drive, Bethesda, MD, 20892-1003, United States. 2. Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Room B3 C346A, 10 Center Drive, Bethesda, MD, 20892-1003, United States. Electronic address: pikev@mail.nih.gov.
Abstract
INTRODUCTION: Metabotropic glutamate subtype receptor 1 (mGluR1) is implicated in several neuropsychiatric disorders and is a target for drug development. [(18)F]FIMX ([(18)F]4-fluoro--N-methyl-N--(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide) is an effective radioligand for imaging brain mGluR1 with PET. A similarly effective radioligand with a shorter half-life would usefully allow PET studies of mGluR1 at baseline and after pharmacological or other challenge on the same day. Here we describe the preparation of [(11)C]FIMX for evaluation in monkey with PET. METHODS: [(11)C]FIMX was prepared via Pd-promoted carbonylation of 1-fluoro-4-iodobenzene with [(11)C]carbon monoxide, aminolysis of the [(11)C]acyl-palladium complex with the requisite Boc-protected amine, and deprotection with HCl in THF. PET scans of [(11)C]FIMX injected into a monkey were performed at baseline and after preblock of mGluR1 with measurement of the arterial input function. RESULTS: The radiosynthesis required 42 min and gave [(11)C]FIMX in about 5% overall decay-corrected radiochemical yield and with a specific activity of about 100 GBq/μmol. PET in rhesus monkey at baseline showed that radioactivity peaked high in receptor-rich cerebellum and much lower in receptor-poor occipital cortex. Radioactivity in cerebellum declined to 32% of peak at 85 min. VT at baseline appeared stable in all brain regions after 60 min. Under mGluR1 pre-blocked condition, radioactivity uptake in all regions declined more rapidly to a low level. Receptor pre-block reduced VT from 13.0 to 1.5 in cerebellum and from 2.9 to 1.4 in occipital cortex. CONCLUSION: [(11)C]FIMX is an effective radioligand for imaging mGluR1 in monkey with PET. Published by Elsevier Inc.
INTRODUCTION:Metabotropic glutamate subtype receptor 1 (mGluR1) is implicated in several neuropsychiatric disorders and is a target for drug development. [(18)F]FIMX ([(18)F]4-fluoro--N-methyl-N--(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide) is an effective radioligand for imaging brain mGluR1 with PET. A similarly effective radioligand with a shorter half-life would usefully allow PET studies of mGluR1 at baseline and after pharmacological or other challenge on the same day. Here we describe the preparation of [(11)C]FIMX for evaluation in monkey with PET. METHODS: [(11)C]FIMX was prepared via Pd-promoted carbonylation of 1-fluoro-4-iodobenzene with [(11)C]carbon monoxide, aminolysis of the [(11)C]acyl-palladium complex with the requisite Boc-protectedamine, and deprotection with HCl in THF. PET scans of [(11)C]FIMX injected into a monkey were performed at baseline and after preblock of mGluR1 with measurement of the arterial input function. RESULTS: The radiosynthesis required 42 min and gave [(11)C]FIMX in about 5% overall decay-corrected radiochemical yield and with a specific activity of about 100 GBq/μmol. PET in rhesus monkey at baseline showed that radioactivity peaked high in receptor-rich cerebellum and much lower in receptor-poor occipital cortex. Radioactivity in cerebellum declined to 32% of peak at 85 min. VT at baseline appeared stable in all brain regions after 60 min. Under mGluR1 pre-blocked condition, radioactivity uptake in all regions declined more rapidly to a low level. Receptor pre-block reduced VT from 13.0 to 1.5 in cerebellum and from 2.9 to 1.4 in occipital cortex. CONCLUSION: [(11)C]FIMX is an effective radioligand for imaging mGluR1 in monkey with PET. Published by Elsevier Inc.
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: Chad J Swanson; Mark Bures; Michael P Johnson; Anni-Maija Linden; James A Monn; Darryle D Schoepp Journal: Nat Rev Drug Discov Date: 2005-02 Impact factor: 84.694
Authors: Sami S Zoghbi; Kacey B Anderson; Kimberly J Jenko; David A Luckenbaugh; Robert B Innis; Victor W Pike Journal: J Pharm Sci Date: 2011-12-13 Impact factor: 3.534
Authors: Amira K Brown; Yasuyuki Kimura; Sami S Zoghbi; Fabrice G Siméon; Jeih-San Liow; William C Kreisl; Andrew Taku; Masahiro Fujita; Victor W Pike; Robert B Innis Journal: J Nucl Med Date: 2008-12 Impact factor: 10.057
Authors: Paolo Zanotti-Fregonara; Vanessa N Barth; Jeih-San Liow; Sami S Zoghbi; David T Clark; Emily Rhoads; Edward Siuda; Beverly A Heinz; Eric Nisenbaum; Bruce Dressman; Elizabeth Joshi; Debra Luffer-Atlas; Matthew J Fisher; John J Masters; Nancy Goebl; Steven L Kuklish; Cheryl Morse; Johannes Tauscher; Victor W Pike; Robert B Innis Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-08 Impact factor: 9.236
Authors: Anton Lindberg; Shuiyu Lu; Sangram Nag; Magnus Schou; Jeih-San Liow; Sami S Zoghbi; Michael P Frankland; Robert L Gladding; Cheryl L Morse; Akihiro Takano; Nahid Amini; Charles S Elmore; Yong Sok Lee; Robert B Innis; Christer Halldin; Victor W Pike Journal: Nucl Med Biol Date: 2019-01-26 Impact factor: 2.408